The activity of platinum, iridium and rhodium drug complexes against Leishmania donovani

The activities of twenty seven Platinum, Rhodium and Iridium drug complexes were determined against Leishmania donovani amastigotes in mouse peritoneal macrophages in vitro. Eight compounds showed antileishmanial activity of which only three, Rh(III)-mepacrine, Ir(III) pyrrolidine dithiocarbamate an...

Full description

Saved in:
Bibliographic Details
Published inTropical medicine and parasitology Vol. 43; no. 1; p. 24
Main Authors Croft, S L, Neal, R A, Craciunescu, D G, Certad-Fombona, G
Format Journal Article
LanguageEnglish
Published Germany 01.03.1992
Subjects
Animals
Iridium - pharmacology
Iridium - therapeutic use
Leishmania donovani - drug effects
Leishmania donovani - ultrastructure
Leishmaniasis, Visceral - drug therapy
Male
Mice
Microscopy, Electron
Organometallic Compounds - pharmacology
Organometallic Compounds - therapeutic use
Organoplatinum Compounds - pharmacology
Organoplatinum Compounds - therapeutic use
Rhodium - pharmacology
Rhodium - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:The activities of twenty seven Platinum, Rhodium and Iridium drug complexes were determined against Leishmania donovani amastigotes in mouse peritoneal macrophages in vitro. Eight compounds showed antileishmanial activity of which only three, Rh(III)-mepacrine, Ir(III) pyrrolidine dithiocarbamate and Ir(III) diethyl dithiocarbamate had ED50 values of less than 1 microM. The two Iridium complexes produced, respectively, a 50% and 39% suppression of L. donovani amastigotes in the liver of BALB/c mice following the subcutaneous administration of 200 mg/kg for 5 consecutive days. Ultrastructural studies suggest that the amastigote kinetoplast-mitochondrion complex is the primary site of action of the Ir and Rh complexes.
ISSN:0177-2392